MedTrace Logo

Omega-3-fatty Acids on Age-related Macular

NCT01258335 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2011-11-22

No results posted yet for this study

Summary

Aim: To demonstrate the short-term multi focal electroretinogram (mfERG) effect of oral omega-3-fatty acids in the triglyceride form on dry age-related macular degeneration (AMD).

Null hypothesis: Omega-3-fatty acids do not affect the mfERGs of patients with dry AMD.

Conditions

  • Aged Macular Degeneration

Interventions

DIETARY_SUPPLEMENT

Omega 3

Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)

OTHER

Olive Oil

ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)

Sponsors & Collaborators

  • LifeGuard

    collaborator UNKNOWN

  • Mid Atlantic Retina

    lead OTHER

Principal Investigators

  • Allen Ho, MD · Retina Specialist

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE

Eligibility

Min Age
20 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01258335 on ClinicalTrials.gov